Remove astrazeneca-face-tough-fda-scrutiny-imfinzi-lynparza-ovarian-cancer-analyst
article thumbnail

AstraZeneca to face tough FDA scrutiny with Imfinzi-Lynparza combo in ovarian cancer: analyst

Fierce Pharma

AstraZeneca to face tough FDA scrutiny with Imfinzi-Lynparza combo in ovarian cancer: analyst aliu Thu, 04/06/2023 - 10:24

FDA 159